> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Blackstone Affiliate Holds 7.6% Of Autolus After Warrants Expire
- URL: https://www.bullished.co/blackstone-affiliate-holds-7-6-of-autolus-after-warrants-expire-0dfadcfd/
- Published: 2026-11-10T21:47:44.000Z
- Updated: 2026-11-10T21:47:44.000Z
- Description: BXLS V - Autobahn's ownership update came from expired warrants, rather than buying or selling shares.
- Author: Matteo Parrino
- Tags: SEC Filings, AUTL, Industry: Healthcare, Topic: Ownership & Activism

BXLS V - Autobahn, a Blackstone-affiliated healthcare investor, reported a [7.6% stake](https://www.sec.gov/Archives/edgar/data/0001393818/000119312526455574/xslSCHEDULE%5F13D%5FX01/primary%5Fdoc.xml?ref=bullished.co) in [Autolus Therapeutics](https://www.bullished.co/tag/autl/), which makes treatments using genetically reprogrammed immune cells, in an amended SEC ownership filing Tuesday. The update followed Friday's expiration of warrants covering 3,265,306 American Depositary Shares, rather than a purchase or sale of Autolus shares.

## The Shares Behind The Stake

BXLS V - Autobahn directly holds [20,485,611 depositary shares](https://www.sec.gov/Archives/edgar/data/0001393818/000119312526455574/xslSCHEDULE%5F13D%5FX01/primary%5Fdoc.xml?ref=bullished.co), each representing one Autolus ordinary share. Warrants give their holders the right to obtain shares; their expiration changed the reported beneficial-ownership calculation without a share trade by the reporting investors.

The 7.6% figure uses 269,662,540 ordinary shares outstanding as of August 10, 2026\. Autolus supplied that share count in a prospectus filed September 22, 2026, so the ownership percentage rests on that dated denominator.

The reporting investors listed sole voting and disposal power over the shares held directly by BXLS V - Autobahn. Blackstone-related entities also reported beneficial ownership through their relationships with the partnership; those entries refer to the same holding, rather than separate blocks of Autolus shares.

BXLS V - Autobahn invests in and helps early-stage and growth-oriented healthcare and life-sciences businesses. Its Autolus ownership record began with a November 16, 2021 disclosure and was amended on December 13, 2022, and May 21, 2024.

## AUCATZYL Anchors Autolus's Business

Autolus's commercial therapy, AUCATZYL, treats adults whose B-cell precursor acute lymphoblastic leukemia has returned or resisted treatment. The company genetically reprograms patients' T cells—a type of immune cell—to target disease.

Autolus sells AUCATZYL in the United States and United Kingdom, where only authorized specialist treatment centers can administer it. Production takes place at the company's Nucleus facility in Stevenage, U.K.; the therapy is available through the National Health Service in England and Wales.

Beyond AUCATZYL, Autolus develops cell therapies for other blood cancers, solid tumors and autoimmune diseases, including lupus and multiple sclerosis. Autolus's market capitalization was $351 million as of 4:42 p.m. ET Tuesday.

For this ownership update, the change was the expiration of rights to obtain shares; BXLS V - Autobahn still directly held 20,485,611 depositary shares.

Learn

- [13D Filing Requirements And Deadline, Shown With Real Filings →](https://www.bullished.co/learn/13d-filing-requirements/)  
A Schedule 13D is required when you own more than 5% of a public company's voting shares. See the deadline, contents and real filings from this week.
- [13D Vs 13G: What Each 5% Stake Filing Means And How To Read One →](https://www.bullished.co/learn/13d-vs-13g/)  
13D vs 13G: both report stakes above 5%, but 13G is the short passive form and 13D explains intent. See real BlackRock and Pictet filings read in plain English.

### Sources

- [SCHEDULE 13D/A — BXLS V - Autobahn L.P. re: Autolus Therapeutics plc (AUTL)](https://www.sec.gov/Archives/edgar/data/0001393818/000119312526455574/xslSCHEDULE%5F13D%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR
- [SCHEDULE 13D/A Exhibit 99.1](https://www.sec.gov/Archives/edgar/data/1393818/000119312526455574/ck0000000000-ex99%5F1.pdf?ref=bullished.co) — SEC EDGAR
- [SCHEDULE 13D/A Exhibit 99.2](https://www.sec.gov/Archives/edgar/data/1393818/000119312526455574/ck0000000000-ex99%5F2.pdf?ref=bullished.co) — SEC EDGAR

### More on Autolus Therapeutics

- [Autolus Stock Sinks 5% After Earnings — Its Multiple-Sclerosis Data Presentation Moves Further Out](https://www.bullished.co/autolus-stock-sinks-5-after-earnings-its-multiple-sclerosis-data-presentation-moves-3de42041/)
- [Autolus Moves MS Data To October 2027 — Its CEO Says Earlier Results Wouldn't Guide Development](https://www.bullished.co/autolus-moves-ms-data-to-october-2027-its-ceo-says-earlier-results-wouldnt-guide-70b18363/)
- [Autolus AUCATZYL Sales Surge 95% — Its Annual Outlook Now Reaches The Former Ceiling](https://www.bullished.co/autolus-aucatzyl-sales-surge-95-its-annual-outlook-now-reaches-the-former-ceiling-13583533/)

[All Autolus Therapeutics (AUTL) coverage →](https://www.bullished.co/tag/autl/)